Abstract
Oncogenic mutations of molecules involved in the mitogen-activated protein kinase (MAPK) pathways provide signals mediating both tumor growth and invasion in various cancers including melanomas. BRAF somatic mutations, found in 66% of melanomas, have NIH3T3 transforming ability with the elevated kinase activity in vitro. We attempted to mediate RNA interference (RNAi) with HIV lentiviral vectors specific for either wild type or the most frequently mutated form of BRAF (V599E) in 10 melanoma cell lines, and found that RNAi inhibited the growth of most melanoma cell lines in vitro as well as in vivo, which was accompanied by decrease of both BRAF protein and ERK phosphorylation. Interestingly, the mutated BRAF (V599E)-specific siRNA inhibited the growth and MAPK activity of only melanoma cell lines with this mutation. Furthermore, BRAF RNAi inhibited matrigel invasion of melanoma cells accompanied with a decrease of matrix metalloproteinase activity and β1 integrin expression. These results clarify that the mutated BRAF (V599E) is essentially involved in malignant phenotype of melanoma cells through the MAPK activation and is an attractive molecular target for melanoma treatment. The lentivirus-mediated RNAi specific for oncogenic mutations may be a powerful technique for gene therapy of cancer.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 50 print issues and online access
$259.00 per year
only $5.18 per issue
Rent or buy this article
Prices vary by article type
from$1.95
to$39.95
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Abbas-Terki T, Blanco-Bose W, Deglon N, Pralong W and Aebischer P . (2002). Hum. Gene Ther., 13, 2197–2201.
Aguirre Ghiso JA, Kovalski K and Ossowski L . (1999). J. Cell Biol., 147, 89–104.
Barton GM and Medzhitov R . (2002). Proc. Natl. Acad. Sci. USA, 99, 14943–14945.
Bernstein E, Caudy AA, Hammond SM and Hannon GJ . (2001). Nature, 409, 363–366.
Brummelkamp TR, Bernards R and Agami R . (2002a). Science, 296, 550–553.
Brummelkamp TR, Bernards R and Agami R . (2002b). Cancer Cell, 2, 243–247.
Cobb MH . (1999). Prog. Biophys. Mol. Biol., 74, 479–500.
Davies H, Bignell GR, Cox C, Stephens P, Edkins S, Clegg S, Teague J, Woffendin H, Garnett MJ, Bottomley W, Davis N, Dicks E, Ewing R, Floyd Y, Gray K, Hall S, Hawes R, Hughes J, Kosmidou V, Menzies A, Mould C, Parker A, Stevens C, Watt S, Hooper S, Wilson R, Jayatilake H, Gusterson BA, Cooper C, Shipley J, Hargrave D, Pritchard-Jones K, Maitland N, Chenevix-Trench G, Riggins GJ, Bigner DD, Palmieri G, Cossu A, Flanagan A, Nicholson A, Ho JWC, Leung SY, Yuen ST, Barbara LW, Seigler HF, Darrow TL, Paterson H, Marais R, Marshall CJ, Wooster R, Stratton MR and Futreal PA . (2002). Nature, 417, 949–954.
Devroe E and Silver PA . (2002). BMC Biotechnol., 28, 15.
Elbashir SM, Harborth J, Lendeckel W, Yalcin A, Weber K and Tuschl T . (2001). Nature, 411, 494–498.
Genersch E, Hayess K, Neuenfeld Y and Haller H . (2000). J. Cell Sci., 113, 521–530.
Hannon GJ . (2002). Nature, 418, 244–251.
Hingorani SR, Jacobetz MA, Robertson GP, Herlyn M and Tuveson DA . (2003). Cancer Res., 63, 5198–5202.
Hynes RO . (1992). Cell, 69, 11–25.
Kawakami Y, Eliyahu S, Delgado CH, Robbins PF, Rivoltini L, Topalian SL, Miki T and Rosenberg SA . (1994). Proc. Natl. Acad. Sci. USA, 91, 3515–3619.
Kawasaki H and Taira K . (2003). Nucleic Acids Res., 31, 700–707.
Lee NS, Dohjima T, Bauer G, Li H, Li MJ, Ehsani A, Salvaterra P and Rossi J . (2002). Nat. Biotechnol., 19, 500–505.
Melchiori A, Mortarini R, Carlone S, Marchisio PC, Anichini A, Noonan DM and Albini A . (1995). Exp. Cell Res., 219, 233–242.
Miyagishi M and Taira K . (2002). Nat. Biotechnol., 19, 497–500.
Miyagishi M, Sumimoto H, Miyoshi H, Kawakami Y and Taira K . J. Gene Med. (in press).
Montgomery AM, Reisfeld RA and Cheresh DA . (1994). Proc. Natl. Acad. Sci. USA, 91, 8856–8860.
Natali PG, Nicotra MR, Bartolazzi A, Cavaliere R and Bigotti A . (1993). Int. J. Cancer, 54, 68–72.
Paddison PJ, Caudy AA, Bernstein E, Hannon GJ and Conklin DS . (2002). Genes Dev., 16, 948–958.
Paul CP, Good PD, Winer I and Engelke DR . (2002). Nat. Biotechnol., 19, 505–508.
Petitclerc E, Stromblad S, von Schalscha TL, Mitjans F, Piulats J, Montgomery AM, Cheresh DA and Brooks PC . (1999). Cancer Res., 59, 2724–2730.
Puyraimond A, Weitzman JB, Babiole E and Menashi S . (1999). J. Cell Sci., 112, 1283–1290.
Qin XF, An DS, Chen ISY and Baltimore D . (2003). Proc. Natl. Acad. Sci. USA, 100, 183–188.
Robbins PF, El-Gamil M, Li YF, Kawakami Y, Loftus D, Apella E and Rosenberg SA . (1996). J. Exp. Med., 183, 1185–1192.
Rubinfeld B, Robbins P, El-Gamil M, Albert I, Porfiri E and Polakis P . (1997). Science, 275, 1790–1792.
Rubinson DA, Dillon CP, Kwiatkowski AV, Sievers C, Yang L, Kopinja J, Zhang M, McManus MT, Gertler FB, Scott ML and Parijs LV . (2003). Nat. Genet., 33, 401–406.
Santibanez JF, Iglesias M, Frontelo P, Martinez J and Quintanilla M . (2000). Biochem. Biophys. Res. Commun., 273, 521–527.
Satyamoorthy K, Li G, Gerrero MR, Brose MS, Volpe P, Weber BL, Belle PV, Elder DE and Herlyn M . (2003). Cancer Res., 63, 756–759.
Smalley KSM . (2003). Int. J. Cancer, 104, 527–532.
Sui G, Soohoo C, Affar EB, Gay F, Shi Y, Forrester WC and Shi Y . (2002). Proc. Natl. Acad. Sci. USA, 99, 5515–5520.
Tiscornia G, Singer O, Ikawa M and Verma IM . (2003). Proc. Natl. Acad. Sci. USA, 100, 1844–1848.
Tuschl T . (2002). Nat. Biotechnol., 20, 446–448.
Vaisanen A, Kallioinen M, von Dickhoff K, Laatikainen L, Hoyhtya M and Turpeenniemi-Hujanen T . (1999). J. Pathol., 188, 56–62.
Woods D, Cherwinski H, Venetsanakos E, Bhat A, Gysin S, Humbert M, Bray PF, Saylor VL and McMahon M . (2001). Mol. Cell. Biol., 21, 3192–3205.
Xia H, Mao Q, Paulson HL and Davidson BL . (2002). Nat. Biotechnol., 20, 1006–1010.
Yu JY, DeRuiter SL and Turner DL . (2002). Proc. Natl. Acad. Sci. USA, 99, 6047–6052.
Acknowledgements
We thank Dr Matsuda for helpful advices and critical review of the manuscript and Drs Okada and Shiomi for helpful advices. This work was supported in part by research grants from the Ministry of Education, Culture, Sports, Science and Technology, research grants from the Ministry of Health, Labour and Welfare and Keio Gijuku Academic Development Funds.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Sumimoto, H., Miyagishi, M., Miyoshi, H. et al. Inhibition of growth and invasive ability of melanoma by inactivation of mutated BRAF with lentivirus-mediated RNA interference. Oncogene 23, 6031–6039 (2004). https://doi.org/10.1038/sj.onc.1207812
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/sj.onc.1207812
Keywords
This article is cited by
-
Tumor-immune profiling of CT-26 and Colon 26 syngeneic mouse models reveals mechanism of anti-PD-1 response
BMC Cancer (2021)
-
Immune-resistant mechanisms in cancer immunotherapy
International Journal of Clinical Oncology (2020)
-
Approaches to treat immune hot, altered and cold tumours with combination immunotherapies
Nature Reviews Drug Discovery (2019)
-
JMJD6 promotes melanoma carcinogenesis through regulation of the alternative splicing of PAK1, a key MAPK signaling component
Molecular Cancer (2017)
-
In vitro prediction of the efficacy of molecularly targeted cancer therapy by Raman spectral imaging
Analytical and Bioanalytical Chemistry (2015)